PD-L1 testing is now cleared to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for anti–PD-1 therapy.
The tool uses results from the CA125 blood test along with a woman's age to generate a personalized risk score for ovarian cancer.
hc1 has launched HerCare, a new module in its MyBloodHealth platform, to enhance maternal health by providing real-time lab-driven insights.
New research reveals that the saliva of pregnant women shows differences in their oral microbiome based on their levels of life stress.
Read More
A study found that faster blood processing could double the detection of gestational diabetes, reducing complications for mothers and babies.
Read More
NIH researchers found undetected cancers in nearly half of pregnant people with abnormal prenatal cfDNA test results.
Read More
Researchers identified genes closely linked to both rheumatoid arthritis and osteoporosis, offering diagnostic markers for these diseases.
Read More
The biomarker could enable prenatal detection of single ventricle heart disease through a maternal blood test for earlier diagnosis.
Read More
A blood test measuring the fibrinogen-to-albumin ratio can predict the risk of preeclampsia in laboring women, improving maternal outcomes.
Read More
Researchers discovered a potential stool test and therapy for endometriosis, based on bacterial metabolites linked to the condition.
Read More
A specific genetic variant found in about 7% of Dutch women reduces the accuracy of NIPT, increasing the likelihood of inconclusive results.
Read More
ClearNote’s ovarian cancer test has been issued a new CPT code by the AMA and preliminary reimbursement rate determinations from CMS.
Read More
A study found that elevated blood levels of LDL cholesterol, Lp(a), and CRP significantly increase long-term cardiovascular risk.
Read More
Endometriosis affects over 11% of women and remains challenging to diagnose early, with researchers exploring new diagnostic methods.
Read More
Researchers are using advanced AI technology, EpiSign, to diagnose rare genetic diseases and prenatal exposure-related birth abnormalities.
Read More
Gattaca Genomics aims to enhance family-building through advanced prenatal genetic screening, increasing the success rates and access.
Read More
A new home-based questionnaire can identify individuals at high risk of heart attacks with the same accuracy as clinical blood tests.
Read More
Menarini Silicon Biosystems presented a study, about its advanced non-invasive prenatal testing technology using maternal blood.
Read More